Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6210731 | 1.00 | LMNA (0.44) | LMNASMN1; SMN2HPGDTHRBALOX12 | |
| SCHEMBL6210717 | 1.00 | LMNA (0.44) | LMNASMN1; SMN2HPGDTHRBALOX12 | |
| SCHEMBL27561727 | 0.82 | LMNA (0.48) | LMNASMN1; SMN2HPGDTHRBALOX12 | |
| SCHEMBL27501950 | 0.82 | LMNA (0.48) | LMNASMN1; SMN2HPGDTHRBALOX12 | |
| SCHEMBL6190987 | 0.81 | LMNA (0.52) | LMNASMN1; SMN2HPGDALDH1A1GAA | |
| SCHEMBL6193183 | 0.81 | LMNA (0.52) | LMNASMN1; SMN2HPGDALDH1A1GAA | |
| SCHEMBL27503054 | 0.81 | LMNA (0.52) | LMNASMN1; SMN2HPGDALDH1A1GAA | |
| SCHEMBL3222312 | 0.80 | MAPT (0.52) | LMNASMN1; SMN2HPGDALDH1A1L3MBTL1 | |
| SCHEMBL3222299 | 0.80 | MAPT (0.52) | LMNASMN1; SMN2HPGDALDH1A1L3MBTL1 | |
| SCHEMBL29643038 | 0.80 | MAPT (0.52) | LMNASMN1; SMN2HPGDALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1299365-B1 | 2-AMINOTHIAZOLINE DERIVATIVES AND THEIR USE AS NO-SYNTHASE INHIBITORS | AVENTIS PHARMA SA (FR) | 2005-09-28 | — | — | EP | disclosed |
| US-6699895-B2 | CYCLIZING THE TERT-BUTYL-THIOUREA DERIVATIVE TO FORM THE END PRODUCT | AVENTIS PHARMA S.A. (FR) | 2004-03-02 | — | — | US | disclosed |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-26 | — | — | US | disclosed |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | CARRY JEAN-CHRISTOPHE (FR) | 2002-12-12 | — | — | US | disclosed |
| US-6451821-B1 | ADMINISTERING TO A PATIENT A THERAPEUTICALLY EFFECTIVE AMOUNT OF 2-AMINOTHIAZOLINE DERIVATIVES FOR TREATING OR PREVENTING DISEASE CONDITIONS ASSOCIATED WITH AN ABNORMAL PRODUCTION OF NITRIC OXIDE(NO) | AVENTIS PHARMA S.A. (FR) | 2002-09-17 | — | — | US | disclosed |
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | AVENTIS PHARMA S.A. (FR) | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022631-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase | NOS2, NOS3, NOS1 | LMNA 4068/4885SMN1; SMN2 4144/4885HPGD 109/4885 |
| US-20020198243-A1 | 2-aminothiazoline derivatives and process for preparing the same | NOS3, TH, CBR1 | LMNA 3890/4885SMN1; SMN2 2862/4885HPGD 175/4885 |
| US-20020187987-A1 | Use of 2-aminothiazoline derivatives as inhibitors of inducible NO-synthase | NOS2, NOS3, NOS1 | LMNA 4084/4885SMN1; SMN2 4243/4885HPGD 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.